FI895346A0 - Bindande proteiner. - Google Patents

Bindande proteiner.

Info

Publication number
FI895346A0
FI895346A0 FI895346A FI895346A FI895346A0 FI 895346 A0 FI895346 A0 FI 895346A0 FI 895346 A FI895346 A FI 895346A FI 895346 A FI895346 A FI 895346A FI 895346 A0 FI895346 A0 FI 895346A0
Authority
FI
Finland
Prior art keywords
bindande
proteiner
somatomedins
insulin
bind
Prior art date
Application number
FI895346A
Other languages
English (en)
Finnish (fi)
Inventor
Christopher Binkert
Guenther F Heinrich
Juerg Schwander
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of FI895346A0 publication Critical patent/FI895346A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI895346A 1988-11-11 1989-11-09 Bindande proteiner. FI895346A0 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888826451A GB8826451D0 (en) 1988-11-11 1988-11-11 Improvements in/relating to organic compounds

Publications (1)

Publication Number Publication Date
FI895346A0 true FI895346A0 (fi) 1989-11-09

Family

ID=10646720

Family Applications (1)

Application Number Title Priority Date Filing Date
FI895346A FI895346A0 (fi) 1988-11-11 1989-11-09 Bindande proteiner.

Country Status (16)

Country Link
EP (1) EP0369943B1 (fr)
JP (1) JPH0341096A (fr)
AT (1) ATE112311T1 (fr)
AU (1) AU623447B2 (fr)
CA (1) CA2002609A1 (fr)
DE (1) DE68918556D1 (fr)
DK (1) DK564989A (fr)
FI (1) FI895346A0 (fr)
GB (1) GB8826451D0 (fr)
HU (2) HU895607D0 (fr)
IL (1) IL92257A0 (fr)
MY (1) MY104673A (fr)
NZ (1) NZ231333A (fr)
PL (1) PL162290B1 (fr)
PT (1) PT92278B (fr)
ZA (1) ZA898610B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
PT98806B (pt) * 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma molecula de dna, um microorganismo ou linha celular recombinantes, e de producao da igfbp-4 ou um seu fragmento
US5212074A (en) * 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
JPH06503711A (ja) * 1990-08-28 1994-04-28 カイロン　コーポレイション 新規インシュリン様成長因子結合タンパク質（ｉｇｆｂｐ―４）
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US6326154B1 (en) 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
WO1992012243A1 (fr) * 1991-01-08 1992-07-23 Chiron Corporation Nouvelle proteine de fixation du facteur de croissance proche de l'insuline (igfbp-6)
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
WO1994022466A1 (fr) * 1993-04-07 1994-10-13 Synergen, Inc. Procedes d'utilisation de proteines de liaison de facteurs de croissance semblables a l'insuline
JPH09507832A (ja) * 1993-09-20 1997-08-12 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆｂｐ単独またはｉｇｆｂｐとｉｇｆとの複合体による免疫疾患および血液疾患の処置
SE9303784D0 (sv) * 1993-11-16 1993-11-16 Kabi Pharmacia Ab Igf
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU762047B2 (en) 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2001087323A2 (fr) 2000-05-16 2001-11-22 Genentech, Inc. Procede de traitement des lesions du cartilage
WO2002072780A2 (fr) 2001-03-14 2002-09-19 Genentech, Inc. Peptides antagonistes d'igf
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
WO2005033132A2 (fr) 2003-10-03 2005-04-14 Genentech, Inc. Proteines de liaison a l'igf
KR20080047529A (ko) 2005-06-17 2008-05-29 임클론 시스템즈 인코포레이티드 전이성 골암 치료를 위한 수용체 길항제
AU2007212447B2 (en) 2006-02-03 2013-02-21 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
CN111432881A (zh) 2017-09-11 2020-07-17 夏尔人类遗传性治疗公司 用于治疗慢性肺病的方法和组合物
EP4228676A1 (fr) 2020-10-19 2023-08-23 Oak Hill Bio Limited Compositions appropriées pour une utilisation chez des nouveau-nés
WO2023139115A1 (fr) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions et procédés pour réduire l'oxydation d'igf‐1/igfbp
WO2023242439A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Stabilisation vasculaire (nourrissons prématurés)
WO2023242440A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Traitement des poumons chez les nourrissons
WO2023242442A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Procédé de maturation/différenciation de neurones et/ou de modulation du nerf vague
WO2024170612A1 (fr) 2023-02-14 2024-08-22 Oak Hill Bio Limited Traitement de la dérégulation de cicatrisation dans un tissu gi

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
EP0418230B1 (fr) * 1988-04-12 1995-12-27 Amgen Boulder Inc. Procede de potentialisation et d'inhibition de l'activite de facteurs de croissance du type insuline

Also Published As

Publication number Publication date
IL92257A0 (en) 1990-07-26
NZ231333A (en) 1992-10-28
ZA898610B (en) 1991-07-31
ATE112311T1 (de) 1994-10-15
PL162290B1 (pl) 1993-09-30
AU623447B2 (en) 1992-05-14
PT92278A (pt) 1990-05-31
DE68918556D1 (de) 1994-11-03
DK564989A (da) 1990-05-12
DK564989D0 (da) 1989-11-10
EP0369943B1 (fr) 1994-09-28
CA2002609A1 (fr) 1990-05-11
MY104673A (en) 1994-05-31
HU895607D0 (en) 1990-01-28
JPH0341096A (ja) 1991-02-21
HU895836D0 (en) 1990-01-28
HUT53936A (en) 1990-12-28
AU4453689A (en) 1990-06-07
PT92278B (pt) 1995-09-12
GB8826451D0 (en) 1988-12-14
EP0369943A1 (fr) 1990-05-23

Similar Documents

Publication Publication Date Title
FI895346A0 (fi) Bindande proteiner.
DE69021263D1 (de) Fibronektinbindungsprotein und dessen Herstellung.
DK0526452T4 (da) Hybridimmunoglobuliner
HUT55801A (en) Process for producing anti-coagulative peptides marked with radioactivity
SE8204810D0 (sv) Recombinant dna molecule, transformed microorganism and process for producing protein a
ES545725A0 (es) Procedimiento para preparar peptidos de interferon
ES2097835T3 (es) Acidos 8-vinil y 8-etinil-quinolon-carboxilicos.
GR3024379T3 (en) Peptides with organo-protective activity, the process for preparing them and their use in therapy
DE3853446D1 (de) Fibronectinbindungsprotein und dessen Herstellung.
HUT55800A (en) Process for producing anticoagulant peptides
DK38889A (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
HUT53125A (en) Process for producing peptides with anticoagulant activity
ATE35427T1 (de) Rekombinante dna, damit transformierter mikroorganismus und dessen verwendung.
DE59309127D1 (de) Verfahren zur Reaktivierung von gereinigten Membranproteinen
SE8403929D0 (sv) Recombinant dna molecule, transformed microorganisms and process for producing penicillin v amidase
ATE110112T1 (de) Verfahren und systeme zur herstellung von hiv- antigenen.

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: SANDOZ AG